GA
NBIX icon

Gateway Advisory’s Neurocrine Biosciences NBIX Stock Holding History

Gateway Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$329K Buy
2,856
+547
+24% +$75K 0.05% 112
2024
Q2 		$318K Buy
2,309
+15
+0.7% +$2.06K 0.05% 118
2024
Q1 		$316K Buy
2,294
+35
+2% +$4.78K 0.06% 110
2023
Q4 		$298K Sell
2,259
-50
-2% -$5.75K 0.06% 91
2023
Q3 		$260K Buy
+2,309
New +$243K 0.05% 83
2014
Q1 		– Sell
-11,000
Closed -$103K – 48
2013
Q4 		$103K Buy
+11,000
New +$107K 0.06% 40

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gateway Advisory's NBIX Position: Q3 2024 in Review

Gateway Advisory increased its Neurocrine Biosciences (NBIX) stake by 24% in Q3 2024, buying an estimated $75K and bringing the position to 2,856 shares worth $329K. The position accounts for 0.05% of the portfolio, ranked #112.

Gateway Advisory first reported a position in NBIX in Q4 2013 and has held it in 6 quarters since. 574 funds tracked by Wall St. Rank hold NBIX as of Q3 2024.

  • Gateway Advisory held 2,856 shares of Neurocrine Biosciences worth $329K as of Q3 2024.
  • Gateway Advisory bought 547 Neurocrine Biosciences shares in Q3 2024, an estimated $75K.
  • Neurocrine Biosciences made up 0.05% of Gateway Advisory's portfolio in Q3 2024, its #112 holding.
  • Gateway Advisory first reported a position in Neurocrine Biosciences in Q4 2013 and has held it in 6 quarters since.
  • 574 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2024.

Based on Gateway Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.